Description
Pharmacological action of
Meldonium, an analogue of gamma-butyrobetaine, inhibits gamma-butyrobate thainhydroxinase, reduces carnitine synthesis and transport of long chain fatty acids through cell membranes, and prevents the accumulation of activated forms of unoxidized carboxylic acid-derived amino acids in cells. decrease in carnitine concentration is intensely synthesized by gamma-butyrobetaine, possessing vasodilating properties.
Under conditions of ischemia, it restores the balance of the processes of oxygen delivery and its consumption in cells, prevents impaired ATP transport, and simultaneously activates glycolysis, which proceeds without additional oxygen consumption.
The mechanism of action determines the diversity of its pharmacological effects: increased efficiency, decreased symptoms of mental and physical stress, activation of tissue and humoral immunity, cardioprotective effect. In the case of acute ischemic damage to the myocardium, it slows down the formation of the necrotic zone and shortens the rehabilitation period. In heart failure, it increases myocardial contractility, increases exercise tolerance, and reduces the frequency of angina attacks. In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the focus of ischemia, contributes to the redistribution of blood in favor of the ischemic area. Effective in case of vascular and dystrophic ocular fundus pathology. A tonic effect on the central nervous system, elimination of functional disorders of the somatic and autonomic nervous systems in patients with alcoholism during the period of withdrawal is also characteristic.
Indications
As part of combination therapy for coronary heart disease, chronic heart failure, cardialgia against the background of dishormonal myocardial dystrophy.
Disorders of the blood supply to the brain (stroke, cerebrovascular insufficiency). Combined therapy of withdrawal alcohol syndrome.
Reduced performance, chronic physical stress, postoperative period to accelerate rehabilitation processes.
Contraindications
Hypersensitivity to the drug, increased intracranial pressure (with impaired venous outflow and intracranial tumors), pregnancy, lactation, age under 18 years (efficacy and safety have not been established).
Special instructions
May give a positive result when conducting a doping control.
Composition
1 caps. contains: Active substances: meldonium dihydrate (trimethylhydrazinium propionate dihydrate) – 250 mg
Dosage and administration
Inside, before meals.
Stable angina pectoris, chronic heart failure – as part of complex therapy at 500-1000 mg per day, using the entire dose at once or dividing it by 2 times. The course of treatment is 4-6 weeks.
Cardialgia against the background of dishormonal myocardial dystrophy – 250 mg 2 times a day (morning and evening). The course of treatment is 12 days.
Disorders of the blood supply to the brain (stroke, cerebrovascular insufficiency) – 500-1000 mg per day, preferably in the morning. The course of treatment is 4-6 weeks. Withdrawal alcohol syndrome – 500 mg 4 times a day. The course of treatment is 7-10 days.
With a decrease in performance and chronic physical stress in the postoperative period to accelerate the rehabilitation process – 250 mg 4 times a day. The course of treatment is 10-14 days. If necessary, the treatment is repeated after 2-3 weeks. Athletes are prescribed 500-1000 mg 2 times a day before training. The duration of the course in the preparatory period is 14-21 days, during the competition period – 10-14 days.
Side effects
Rarely – allergic reactions (redness of the skin, itching, swelling), dyspeptic symptoms, tachycardia, agitation, decreased blood pressure.
Active ingredient
Meldonium
Dispensing conditions from
pharmacies Without a prescription
Dosage form
capsules
